Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA EBITDA Margin
EBITDA as a percentage of revenue.
Privia Health Group, Inc.NASDAQ: PRVA
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 3.2%
EBITDA Margin was 3.2% in Q2 FY2026, up 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 2.9%, up 0.9 pp year over year. Over 3 fiscal years it widened by 3.6 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 2.7% for the fiscal year ending Dec 2026, up from 2.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 3.2%+1.1 pp QoQ
- Last fiscal yearDec 2025
- 2.5%+0.5 pp YoY
- LTMJun 2026
- 2.9%+0.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.6 pp | +0.3 pp | -1.2 pp |
| 1 year | +0.5 pp | +0.2 pp | -0.3 pp |
| 3 years | +3.6 pp | +2.0 pp | -1.5 pp |
| 5 years | +2.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 2.5%
- Year-over-year change
- +0.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.5% | +0.5pp |
| FY2024 | 2024-12-31 | 2.0% | -0.1pp |
| FY2023 | 2023-12-31 | 2.1% | +3.2pp |
| FY2022 | 2022-12-31 | -1.0% | +21.2pp |
| FY2021 | 2021-12-31 | -22.2% | — |
EBITDA Margin vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 EBITDA Margin of 2.9% is the 4th highest of the 10 companies compared; the peer median is 0.2%.
- Its year-over-year change of +0.9 pp is the 6th highest of 10, against a peer median of +1.0 pp.
- Over three fiscal years its change of +3.6 pp compares with a peer median of +6.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 22.8% | +1.3 pp | +8.3 pp | |
| LTM Apr 2026 | 8.6% | +10.7 pp | +57.9 pp | |
| LTM Mar 2026 | 4.6% | -1.1 pp | -5.5 pp | |
| LTM Jun 2026 | 2.9% | +0.9 pp | +3.6 pp | |
| LTM Mar 2026 | 2.3% | +1.0 pp | +6.1 pp | |
| LTM Mar 2026 | 0.2% | +15.0 pp | +69.9 pp | |
| LTM Mar 2026 | -5.9% | -2.2 pp | -3.2 pp | |
| LTM Mar 2026 | -16.7% | -18.0 pp | -22.5 pp | |
| LTM Mar 2026 | -22.3% | +24.7 pp | +64.4 pp | |
| LTM Mar 2026 | -63.6% | -59.1 pp | -5.5 pp | |
| Peer median (excluding PRVA) | 0.2% | +1.0 pp | +6.1 pp | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 966.22M | 1.36B | 1.66B | 1.74B | 2.12B |
| Cost of Revenue | 902.56M | 1.22B | 1.5B | 1.56B | 1.91B |
| Gross Profit | 63.66M | 134.78M | 161.5M | 176.85M | 209.43M |
| Gross Margin | 6.6% | 9.9% | 9.7% | 10.2% | 9.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 278.63M | 149.33M | 134.32M | 152.6M | 165.29M |
| Operating Expenses | 281.1M | 153.9M | 140.85M | 159.87M | 175.2M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| EBITDA | (214.97M) | (14.01M) | 35.55M | 35.14M | 53.85M |
| EBITDA Margin | -22.2% | -1.0% | 2.1% | 2.0% | 2.5% |
| Operating Income | (217.44M) | (19.12M) | 20.65M | 16.98M | 34.24M |
| Operating Margin | -22.5% | -1.4% | 1.2% | 1.0% | 1.6% |
| Interest Income | 0 | 542K | 8.37M | 10.89M | 9.7M |
| Interest Expense | 1.07M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.07M) | 542K | 8.37M | 10.89M | 9.7M |
| Income Before Tax | (218.51M) | (18.58M) | 29.02M | 27.87M | 43.94M |
| Pre-Tax Margin | -22.6% | -1.4% | 1.8% | 1.6% | 2.1% |
| Income Tax Expense | (27.86M) | (6.52M) | 7.99M | 10.83M | 14.21M |
| Net Income | (188.23M) | (8.59M) | 23.08M | 14.39M | 22.92M |
| Net Margin | -19.5% | -0.6% | 1.4% | 0.8% | 1.1% |
| EPS (Basic) | (1.77) | (0.08) | 0.20 | 0.12 | 0.19 |
| EPS (Diluted) | (1.77) | (0.08) | 0.19 | 0.11 | 0.18 |
| Weighted Avg Shares | 107.84M | 110.7M | 116.73M | 119.4M | 122.18M |
| Weighted Avg Shares (Diluted) | 107.84M | 110.7M | 124.69M | 125.61M | 128.89M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.